Citations

Mayo Clinic

Showing 10 of 108106 citations.

A major role for carbon monoxide as an endogenous hyperpolarizing factor in the gastrointestinal tract
Farrugia, Gianrico , Lei, Sha, Lin, Xue , Miller, Steven M. , Nath, Karl A. , Ferris, Christopher D., Levitt, Michael D. , Szurszewski, Joseph H., Sha, Lei , Lei, Sha

Proceedings of the National Academy of Sciences | July 8, 2003 | Volume: 100 | Issue: 14 | Pages: 8567-8570

10.1073/pnas.1431233100 | PMID 12832617 Get It

Carbon monoxide (CO) is proposed as a physiological messenger. CO activates cGMP and has a direct effect on potassium channels. Both actions of CO lead to hyperpolarization of a cell's resting membrane potential, suggesting that CO may function as a hyperpolarizing factor, although direct evidence is still lacking. Here we take advantage of the known membrane potential gradient that exists in the muscle layers of the gastrointestinal tract to determine whether CO is an endogenous hyperpolarizing factor. We find that heme oxygenase-2-null mice have depolarized smooth muscle cells and that the membrane potential gradient in the gut is abolished. Exogenous CO hyperpolarizes the membrane potential. Regions of the canine gastrointestinal tract that are more hyperpolarized generate more CO and have higher heme oxygenase activity than more depolarized regions. Our results suggest that CO is a critical hyperpolarizing factor required for the maintenance of intestinal smooth muscle membrane potential and gradient.
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
Pardanani, Animesh , Ketterling, Rhett P. , Brockman, Stephanie R., Flynn, Heather C., Paternoster, Sarah F., Shearer, Brandon M., Reeder, Terra L. , Li, Chin‐Yang, Cross, Nicholas C.P. , Cools, Jan , Gilliland, D. Gary, Dewald, Gordon W., Tefferi, Ayalew , Li, Chin‐Yang, Ketterling, Rhett P , Cross, Nicholas C P

Blood | July 8, 2003 | Volume: 102 | Issue: 9 | Pages: 3093-3096

10.1182/blood-2003-05-1627 | PMID 12842979 Get It

AbstractImatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either abl- or PDGFRβ- activating mutations. The drug is also active in a subset of patients with eosinophilic disorders and systemic mast cell disease (SMCD). Recently, a novel tyrosine kinase that is generated from fusion of the Fip1-like 1 (FIP1L1) and PDGFRα (PDGFRA) genes has been identified as a therapeutic target for imatinib mesylate in hypereosinophilic syndrome (HES). We used fluorescence in situ hybridization (FISH) to detect deletion of the CHIC2 locus at 4q12 as a surrogate for the FIP1L1-PDGFRA fusion. CHIC2 deletion was observed in bone marrow cells for 3 of 5 patients with SMCD associated with eosinophilia. Deletion of this locus and expression of the FIP1L1–platelet-derived growth factor receptor α (PDGFRA) fusion was also documented in enriched eosinophils, neutrophils, or mononuclear cells by both FISH and reverse transcriptase–polymerase chain reaction (RT-PCR) for one patient. While all 3 patients with the FIP1L1-PDGFRA rearrangement achieved a sustained complete response with imatinib mesylate therapy, the other two, both carrying the c-kit Asp816 to Val (Asp816Val) mutation, did not. These observations suggest that the FIP1L1-PDGFRA rearrangement occurs in an early hematopoietic progenitor and suggests that the molecular pathogenesis for a subset of SMCD patients is similar to that of HES. Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD.
Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor
Shin, Tahiro, Kennedy, Gene, Gorski, Kevin, Tsuchiya, Haruo, Koseki, Haruhiko , Azuma, Miyuki , Yagita∥, Hideo , Powell, Jonathan D. , Pardoll, Drew M. , Housseau, Franck , Chen, Lieping

The Journal of Experimental Medicine | July 7, 2003 | Volume: 198 | Issue: 1 | Pages: 31-38

10.1084/jem.20030242 | PMID 12847135 Get It

B7-DC is a recently discovered member of the B7 family that binds to PD-1 and is selectively expressed by dendritic cells (DCs). It has been shown to either costimulate or inhibit T cell responses. To assess the role of B7-DC in DC–T cell interactions, DCs from B7-DC knockout (KO) mice were generated and compared with DCs from wild-type (WT) and B7–1/B7–2 double KO mice. B7–1/B7–2–deficient DCs, while strongly diminished in their ability to stimulate naive CD4+ T cells, nonetheless retain partial activity. DCs from B7-DC KO mice are diminished in their ability to activate CD4+ T cells, demonstrating that DC-expressed B7-DC serves a predominantly stimulatory rather than inhibitory function in the initiation of T cell responses. B7-DC costimulates expression of CD40L with faster kinetics than B7–1 and displays potent synergy with B7–1 and B7–2 for T cell proliferation and cytokine production, indicating that these B7 family members work in concert to stimulate T cells. Finally, costimulation with B7-DC alone or in conjunction with B7–1 is PD-1 independent, indicating that B7-DC costimulates T cells via a second receptor.
Sleep-Disordered Breathing and Cardiovascular Disease
Wołk, Robert , Kára, Tomáš, Somers, Virend K.

Circulation | July 7, 2003 | Volume: 108 | Issue: 1 | Pages: 9-12

10.1161/01.cir.0000072346.56728.e4 | PMID 12847053 Get It

Clinical Diagnosis of Hypersensitivity Pneumonitis
Lacasse, Yves , Selman, Moisés , Costabel, Ulrich , Dalphin, Jean‐Charles, Ando, Masayuki, Morell, Ferrán , Erkinjuntti‐Pekkanen, R., Müller, Néstor L. , Colby, Thomas V. , Schuyler, Mark, Cormier, Yvon

American Journal of Respiratory and Critical Care Medicine | July 7, 2003 | Volume: 168 | Issue: 8 | Pages: 952-958

10.1164/rccm.200301-137oc | PMID 12842854 Get It

Abstract The diagnosis of hypersensitivity pneumonitis (HP) is difficult and often relies on histopathology. Our objective was to identify diagnostic criteria and to develop a clinical prediction rule for this disease. Consecutive patients presenting a condition for which HP was considered in the differential diagnosis underwent a program of simple standardized diagnostic procedures. High-resolution computed tomography scan and bronchoalveolar lavage (BAL) defined the presence or absence of HP. Patients underwent surgical lung biopsy when the computed tomography scan, BAL, and other diagnostic procedures failed to yield a diagnosis. A cohort of 400 patients (116 with HP, 284 control subjects) provided data for the rule derivation. Six significant predictors of HP were identified: (1) exposure to a known offending antigen, (2) positive precipitating antibodies to the offending antigen, (3) recurrent episodes of symptoms, (4) inspiratory crackles on physical examination, (5) symptoms occurring 4 to 8 hours after exposure, (6) and weight loss. The area under the receiver operating characteristic curve was 0.93 (95% confidence interval: 0.90–0.95). The rule retained its accuracy when validated in a separate cohort of 261 patients. The diagnosis of HP can often be made or rejected with confidence, especially in areas of high or low prevalence, respectively, without BAL or biopsy.
Endothelial Progenitor Cells Are Decreased in Blood of Cardiac Allograft Patients With Vasculopathy and Endothelial Cells of Noncardiac Origin Are Enriched in Transplant Atherosclerosis
Simper, David, Deb, Arjun , Holmes, David R. , McGregor, Christopher G.A. , Frantz, Robert P. , Kushwaha, Sudhir S. , Caplice, Noel M. , Wang, Shaohua , Frantz, Robert P

Circulation | July 1, 2003 | Volume: 108 | Issue: 2 | Pages: 143-149

10.1161/01.cir.0000081703.34526.5d | PMID 12835206 Get It

Background— Recent studies in animals suggest that circulating recipient endothelial precursors may participate in the biology of transplant vasculopathy. It is currently unknown whether a similar interaction between recipient endothelial cells and the vessel wall occurs in human subjects undergoing allogeneic cardiac transplantation. Methods and Results— Circulating endothelial cells and endothelial progenitor cells (EPCs) were quantified in 15 cardiac transplantation subjects with and without angiographic evidence of vasculopathy. In a separate series of experiments, the origin (donor or recipient) of transplant plaque endothelial cells was assessed in subjects who had undergone a gender-mismatched cardiac transplantation and had histological evidence of severe vasculopathy at the time of heart explantation. Circulating EPC outgrowth colonies in peripheral blood were significantly reduced in subjects with transplant vasculopathy compared with those without angiographic evidence of disease (EPC colony-forming units [CFU EPC ]: 4.5±1.9 versus 15.1±3.7, P <0.05). There was no significant difference in circulating endothelial cell numbers as defined by day 4 culture acetylated LDL/lectin assay in either of these patient groups. In a separate group of 5 subjects who underwent gender-mismatched cardiac transplantation, there was a significant seeding of recipient endothelial cells (range: 1% to 24% of all luminal endothelial cells) in large-vessel lumen and adventitial microvessel lumen of arteriopathic vessels. No opposite-sex chimeric cells were observed in control gender-matched transplantation scenarios. Conclusions— These data suggest that the human cardiac transplant arteriopathy is associated with reduction in circulating endothelial precursors and with seeding of recipient-derived endothelial cells at the site of plaque development.
When Your Favorite Patient Relapses: Physician Grief and Well-Being in the Practice of Oncology
Adjei, Alex A. , Meyskens, Frank L. , Shanafelt, Tait D.

Journal of Clinical Oncology | June 30, 2003 | Volume: 21 | Issue: 13 | Pages: 2616-2619

10.1200/jco.2003.06.075 | PMID 12829683 Get It

Effects of Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma Measured by the Folstein Mini-Mental State Examination
Brown, Paul D. , Buckner, Jan C. , OʼFallon, Judith R., Iturria, Nancy, Brown, Cerise A., Scheithauer, Bernd W., Dinapoli, Robert P., Arusell, Robert M., Curran, Walter J. , Abrams, Ross A. , Shaw, Edward G. , O’Neill, Brian Patrick

Journal of Clinical Oncology | June 30, 2003 | Volume: 21 | Issue: 13 | Pages: 2519-2524

10.1200/jco.2003.04.172 | PMID 12829670 Get It

Purpose: To assess the neurocognitive effects of cranial radiotherapy on patients with low-grade gliomas, we analyzed cognitive performance data collected in a prospective, intergroup clinical trial. Methods: Patients included 203 adults with supratentorial low-grade gliomas randomly assigned to a lower dose (50.4 Gy in 28 fractions) or a higher dose (64.8 Gy in 36 fractions) of localized radiotherapy. Folstein Mini-Mental State Examination (MMSE) scores and neurologic function scores (NFS) at baseline and key evaluations were analyzed. Median follow-up was 7.4 years in 101 patients still alive. A change of more than three MMSE points was considered clinically significant. Results: In patients without tumor progression, significant deterioration from baseline occurred at years 1, 2, and 5 in 8.2%, 4.6%, and 5.3% of patients, respectively. Most patients with an abnormal baseline MMSE score (< 27) experienced significant increases. Baseline variables such as radiation dose, conformal versus conventional radiotherapy, number of radiation fields, age, sex, tumor size, NFS, seizures, and seizure medications did not predict cognitive function changes. Conclusion: In this population, most low-grade glioma patients maintained a stable neurocognitive status after focal radiotherapy as measured by the MMSE. Patients with an abnormal baseline MMSE were more likely to have an improvement in cognitive abilities than deterioration after receiving radiotherapy. Only a small percentage of patients had cognitive deterioration after radiotherapy. However, more discriminating neurocognitive assessment tools may identify cognitive decline not apparent with the use of the MMSE.
A novel dynamin III isoform is up-regulated in the central nervous system in hypothyroidism
Arnold, Andrew , Anderson, Grant W., McIver, Bryan, Eberhardt, Norman L.

International Journal of Developmental Neuroscience | June 30, 2003 | Volume: 21 | Issue: 5 | Pages: 267-275

10.1016/s0736-5748(03)00053-4 | PMID 12850060 Get It

Regulation of eosinophil membrane depolarization during NADPH oxidase activation
Bankers‐Fulbright, Jennifer L., Gleich, Gerald J. , Kephart, Gail M., Kita, Hirohito , O’Grady, Scott M. , Kita, H

Journal of Cell Science | June 26, 2003 | Volume: 116 | Issue: 15 | Pages: 3221-3226

10.1242/jcs.00627 | PMID 12829741 Get It

Protein kinase C (PKC) activation in human eosinophils increases NADPH oxidase activity, which is associated with plasma membrane depolarization. In this study, membrane potential measurements of eosinophils stimulated with phorbol ester (phorbol 12-myristate 13-acetate; PMA) were made using a cell-permeable oxonol membrane potential indicator, diBAC4(3). Within 10 minutes after PMA stimulation, eosinophils depolarized from–32.9±5.7 mV to +17.3±1.8 mV. The time courses of depolarization and proton channel activation were virtually identical. Blocking the proton conductance with 250 μM ZnCl2(+43.0±4.2 mV) or increasing the proton channel activation threshold by reducing the extracellular pH to 6.5 (+44.4±1.4 mV) increased depolarization compared with PMA alone. Additionally, the protein kinase C(PKC) δ-selective blocker, rottlerin, inhibited PMA-stimulated depolarization, indicating that PKCδ was involved in regulating depolarization associated with eosinophil NADPH oxidase activity. Thus, the membrane depolarization that is associated with NADPH oxidase activation in eosinophils is sufficient to produce marked proton channel activation under physiological conditions.